MDT

88.81

-0.56%↓

VEEV

279.44

-0.49%↓

A

115.03

+1.83%↑

WBA

11.52

+0.17%↑

HQY

99

+1.86%↑

MDT

88.81

-0.56%↓

VEEV

279.44

-0.49%↓

A

115.03

+1.83%↑

WBA

11.52

+0.17%↑

HQY

99

+1.86%↑

MDT

88.81

-0.56%↓

VEEV

279.44

-0.49%↓

A

115.03

+1.83%↑

WBA

11.52

+0.17%↑

HQY

99

+1.86%↑

MDT

88.81

-0.56%↓

VEEV

279.44

-0.49%↓

A

115.03

+1.83%↑

WBA

11.52

+0.17%↑

HQY

99

+1.86%↑

MDT

88.81

-0.56%↓

VEEV

279.44

-0.49%↓

A

115.03

+1.83%↑

WBA

11.52

+0.17%↑

HQY

99

+1.86%↑

Search

STAAR Surgical Co

Open

SectorGezondheidszorg

17.31 1.35

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

17.01

Max

17.4

Belangrijke statistieken

By Trading Economics

Inkomsten

-20M

-54M

Verkoop

-6.4M

43M

K/W

Sectorgemiddelde

55.443

39.857

Winstmarge

-127.289

Werknemers

1,157

EBITDA

-43M

-71M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+11.18% upside

Dividenden

By Dow Jones

Volgende Winsten

6 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

64M

857M

Vorige openingsprijs

15.96

Vorige sluitingsprijs

17.31

Nieuwssentiment

By Acuity

50%

50%

161 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

STAAR Surgical Co Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 jul 2025, 23:56 UTC

Acquisities, Fusies, Overnames

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- 2nd Update

16 jul 2025, 23:43 UTC

Acquisities, Fusies, Overnames

Santos 2Q Output Rises 1% as Takeover Campaign Continues

16 jul 2025, 23:00 UTC

Acquisities, Fusies, Overnames

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- Update

16 jul 2025, 22:38 UTC

Acquisities, Fusies, Overnames

Alimentation Couche-Tard Withdraws Seven & i Acquisition Proposal

16 jul 2025, 23:44 UTC

Marktinformatie

Gold Steady; Geopolitical Tensions in Middle East Support -- Market Talk

16 jul 2025, 23:42 UTC

Marktinformatie

Nikkei May Fall as Yen Strengthens -- Market Talk

16 jul 2025, 23:24 UTC

Marktinformatie

Australian Job Market Data to Shape RBA Calls -- Market Talk

16 jul 2025, 23:18 UTC

Acquisities, Fusies, Overnames

Santos Now Expects 2025 Production of 90 Million-95 Million BOE

16 jul 2025, 23:18 UTC

Acquisities, Fusies, Overnames

Santos Cuts Top End of 2025 Production Guidance

16 jul 2025, 23:17 UTC

Acquisities, Fusies, Overnames

Santos: Production Recovery Underway in Cooper Basin

16 jul 2025, 23:17 UTC

Acquisities, Fusies, Overnames

Santos: Over 200 Wells, Several Upstream Compressors in Cooper Basin Shut In

16 jul 2025, 23:17 UTC

Acquisities, Fusies, Overnames

Santos: Cooper Basin Production Impacted by Floods in 2Q

16 jul 2025, 23:16 UTC

Acquisities, Fusies, Overnames

Santos: Pikka Phase 1 Project in Alasia 89% Complete

16 jul 2025, 23:16 UTC

Acquisities, Fusies, Overnames

Santos Keeps 2025 Major Development Project Capex Guidance Unchanged

16 jul 2025, 23:13 UTC

Acquisities, Fusies, Overnames

Santos Had Gearing of 20.5% at End-June, Excluding Operating Leases

16 jul 2025, 23:13 UTC

Acquisities, Fusies, Overnames

Santos Says Moomba CCS Phase 1 Project Performing to Expectations

16 jul 2025, 23:12 UTC

Acquisities, Fusies, Overnames

Santos Narrows 2025 Unit Production Cost Guidance to US$7.00-US$7.40/BOE

16 jul 2025, 23:12 UTC

Acquisities, Fusies, Overnames

Santos 1H Free Cash Flow From Operations US$1.1 Billion

16 jul 2025, 23:11 UTC

Acquisities, Fusies, Overnames

Santos 2Q Free Cash Flow From Operations US$620 Million

16 jul 2025, 23:11 UTC

Acquisities, Fusies, Overnames

Santos 2Q Oil, Natural Gas Output 22.2 Million BOE

16 jul 2025, 23:11 UTC

Acquisities, Fusies, Overnames

Santos 2Q Oil, Natural Gas Sales Volumes 23.9 Million BOE

16 jul 2025, 23:11 UTC

Acquisities, Fusies, Overnames

Santos 2Q Oil, Natural Gas Sales Volumes Up 3% on 1Q

16 jul 2025, 23:11 UTC

Acquisities, Fusies, Overnames

Santos 2Q Oil, Natural Gas Output Up 1% on 1Q

16 jul 2025, 22:43 UTC

Marktinformatie

Alcoa Using High Costs of More Production to Battle Tariff -- Market Talk

16 jul 2025, 22:35 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

16 jul 2025, 22:35 UTC

Marktinformatie
Winsten

Replacing Aluminum Imports With U.S. Production Not Seen Feasible -- Market Talk

16 jul 2025, 22:33 UTC

Marktinformatie
Winsten

Alcoa Will Continue to Ship Aluminum Outside of the U.S. -- Market Talk

16 jul 2025, 22:28 UTC

Marktinformatie
Winsten

Aluminum Price in U.S. Doesn't Offset Tariff Costs, Alcoa says -- Market Talk

16 jul 2025, 22:22 UTC

Marktinformatie
Winsten

Market Talk Roundup: Latest on U.S. Politics

16 jul 2025, 22:22 UTC

Marktinformatie
Winsten

Alcoa Considers Restart of Idle Capacity at Indiana Smelter -- Market Talk

Peer Vergelijking

Prijswijziging

STAAR Surgical Co Prognose

Koersdoel

By TipRanks

11.18% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 19 USD  11.18%

Hoogste 27 USD

Laagste 13 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor STAAR Surgical Co - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

10 ratings

2

Buy

7

Hold

1

Sell

Technische score

By Trading Central

18.604 / 20.07Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Very Strong Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

161 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over STAAR Surgical Co

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.